Description
From Wall Street Darling To Turnaround Story: Dexcom Lost Billions—Now Elliott Wants A Reset!
DexCom, Inc. is no longer being judged only as a high-growth medical device winner. It is now being judged as a fallen market favorite trying to rebuild credibility. The company’s market value once peaked above $63 billion in 2021, but it had fallen to roughly $23 billion before activist investor Elliott Investment Management disclosed a stake and reached a board settlement. The deal will add two independent directors with medical technology and operations experience, marking another step in Dexcom’s broader governance reset. The timing is significant. Dexcom has faced execution missteps, revenue outlook cuts, reimbursement questions, and rising competition in continuous glucose monitoring. Yet its latest earnings call also showed a business that is not standing still: revenue grew, margins improved, Type 2 access expanded, and management outlined product updates aimed at rebuilding customer trust.
